CIK 0001668243
- Non-accelerated filer
- Smaller reporting company
UroGen Pharma Ltd.
Sign in to watch- Ticker
- URGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 97707601
- Business address
- 9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
- 4 Open-market sale Chief Medical Officer sold 107 shares at $16.32 ($1,746)
- 4 Open-market sale Chief Medical Officer sold 243 shares at $15.64 ($3,801)
- 4 Open-market sale Chief Medical Officer sold 103 shares at $15.30 ($1,576)
- 4/A Exercise or conversion Chief Executive Officer acquired 61,652 shares (option exercise)
- 4/A Exercise or conversion Chief Executive Officer acquired 35,229 shares (option exercise)
- 4/A Exercise or conversion Director acquired 3,241 shares (option exercise)
- 4/A Exercise or conversion Director acquired 1,030 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Director acquired 2,211 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Shares withheld for taxes Chief Executive Officer gave up 3,425 shares (to pay taxes)
- 4 Open-market buy Chief Financial Officer bought 2,500 shares at $15.85 ($39,625)
- 4 Open-market buy General Counsel bought 2,500 shares at $15.71 ($39,275)
- 4 Open-market sale Chief Medical Officer sold 243 shares at $20.00 ($4,860)
Page 7 of 12 · 233 filings